ArticleTherapeutic advances in musculoskeletal disease2026
Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and the incidence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) remains unclear. Objective: To investigate the influence of b/tsDMARDs on the development of ILD in patients with RA, particularly in Asian patients. Design: Retrospective cohort study. Methods: We examined data from patients with seropositive RA who had no prior ILD between January 1, 2010, and October 31, 2022, utilizing the Nationwide Korean Health Insurance Review and Assessment database. Cohort A consisted of individuals initiating b/tsDMARDs, while Cohort B included those starting conventional DMARDs, including individuals who subsequently began b/tsDMARDs. Patients were observed from the medication index date until the onset of ILD, death, or the conclusion of the study. In Cohort A, multivariate Cox proportional hazards analysis was conducted, followed by propensity score matching (PSM) analysis. In Cohort B, a time-dependent Cox proportional hazards analysis was performed, accounting for methotrexate (MTX) pretreatment period. Results: In Cohort A (13,908 patients), the crude incidence rate (IR) of ILD was 3.05 per 1000 person-years. After multivariable adjustment and PSM, no statistically significant differences in ILD development were observed among the biologics classes, with hazard ratios (HRs) ranging from 0.81 to 1.19 when compared to tumor necrosis factor (TNF) inhibitors as a reference. In Cohort B (75,013 patients), the overall IR was 2.8 per 1000 person-years. Time-dependent multivariable Cox analysis, adjusting for baseline characteristics and MTX pretreatment duration, showed no statistically significant differences between biologic users and MTX maintainers (adjusted HR range: 0.74-1.29, all Conclusion: No specific b/tsDMARDs consistently showed significant differences in ILD incidence compared to other b/tsDMARDs. Biologics showed no significant increase in the risk of ILD compared to MTX maintainers. TNF inhibitors performed similarly to non-TNF biologics and Janus kinase inhibitors in terms of ILD incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.